Show Brain Metastases 2012

Brain Metastases 2012


Scientific Program 2012-09-05


See all
Click on the following buttons to choose the program topics that interest you.
By sessions
Pathobiology of brain metastases
Targeted therapy (part 1)
Targeted therapy (part 2)
Multimodal imaging
Local treatment
Neurocognitive function in Brain Metastases patients
European perspectives and collaborations


09.15 - 09.45

Welcome to participant - Coffee

09.45 - 10.00

Introduction

10.00 - 10.25
Pathobiology of brain metastases

New insights in the molecular characterization of brain metastases

10.35 - 11.00
Pathobiology of brain metastases

Micro-RNA-based identification of the primary tumor tissue

Attached file :
11.10 - 11.35
Targeted therapy (part 1)

Gene signature to predict rapid development of brain metastases in HER2-positive advanced breast cancer patients

Attached file :
11.45 - 12.10
Targeted therapy (part 1)

Correlation between quantitative HER-2 protein expression and risk for brain metastase

Attached file :
12.45 - 13.15

Lunch

13.15 - 14.15

Symposium on Targeted Therapies

14.15 - 14.40
Targeted therapy (part 2)

Brain metastases in HER2+ BC and Landscape trial: toward a change of paradigm

Attached file :
14.50 - 15.15
Multimodal imaging

MRI changes interpretation following radiosurgical treatment of brain metastases

15.30 - 15.55
Multimodal imaging

New imaging techniques in brain metastases diagnosis and follow-up

16.00 - 16.30

Coffee break

16.30 - 16.55
Local treatment

Place of surgery in diagnostic and therapeutic strategies: New challenges

Attached file :
17.00 - 17.25
Local treatment

Place of tumor bed radiosurgery and focal radiotherapy following resection of brain metastases: A new paradigm

Attached file :
17.30 - 17.55
Neurocognitive function in Brain Metastases patients

Neurocognition in patients with brain metastase

Attached file :
18.00 - 19.30

Poster session

19.30 - 21.00
European perspectives and collaborations

Interaction with the industry and development of emerging targeted therapies

19.30 - 21.00
European perspectives and collaborations

Open discussion on future clinical trials delineation in brain metastases

Top